TY - JOUR
T1 - De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity
T2 - The M. D. Anderson and Mayo Clinic experience
AU - Tam, Constantine S.
AU - Shanafelt, Tait D.
AU - Wierda, William G.
AU - Abruzzo, Lynne V.
AU - Van Dyke, Daniel L.
AU - O'Brien, Susan
AU - Ferrajoli, Alessandra
AU - Lerner, Susan A.
AU - Lynn, Alice
AU - Kay, Neil E.
AU - Keating, Michael J.
PY - 2009
Y1 - 2009
N2 - To determine the clinical fate of patients with de novo deletion 17p13.1 (17p-) chronic lymphocytic leukemia (CLL), we retrospectively studied the outcome of 99 treatment-naive 17p- CLL patients from the M. D. Anderson Cancer Center (n = 64) and the Mayo Clinic (n = 35). Among 67 asymptomatic patients followed for progression, 53% developed CLL requiring treatment over 3 years. Patients who had not progressed by 18 months subsequently had stable disease, with 3 of 19 patients progressing after follow-up of up to 70 months. Risk factors for progressive disease were Rai stage of 1 or higher and unmutated immunoglobulin variable region heavy chain (IgVH). The overall survival rate was 65% at 3 years. Rai stage 1 or higher, unmutated IgVH, and 17p- in 25% or more of nuclei were adverse factors for survival. The 3-year survival rates of patients with 1 or fewer, 2, and 3 of these factors were 95%, 74%, and 22%, respectively (P < .001). Response rates to therapy with rituximab (n = 6); purine analogues and rituximab (n = 25); and purine analogues, rituximab, and alemtuzumab (n = 16) combinations were 50%, 72%, and 81%, respectively. Patients with 17p-CLL exhibit clinical heterogeneity, with some patients experiencing an indolent course. Survival can be predicted using clinical and biologic characteristics.
AB - To determine the clinical fate of patients with de novo deletion 17p13.1 (17p-) chronic lymphocytic leukemia (CLL), we retrospectively studied the outcome of 99 treatment-naive 17p- CLL patients from the M. D. Anderson Cancer Center (n = 64) and the Mayo Clinic (n = 35). Among 67 asymptomatic patients followed for progression, 53% developed CLL requiring treatment over 3 years. Patients who had not progressed by 18 months subsequently had stable disease, with 3 of 19 patients progressing after follow-up of up to 70 months. Risk factors for progressive disease were Rai stage of 1 or higher and unmutated immunoglobulin variable region heavy chain (IgVH). The overall survival rate was 65% at 3 years. Rai stage 1 or higher, unmutated IgVH, and 17p- in 25% or more of nuclei were adverse factors for survival. The 3-year survival rates of patients with 1 or fewer, 2, and 3 of these factors were 95%, 74%, and 22%, respectively (P < .001). Response rates to therapy with rituximab (n = 6); purine analogues and rituximab (n = 25); and purine analogues, rituximab, and alemtuzumab (n = 16) combinations were 50%, 72%, and 81%, respectively. Patients with 17p-CLL exhibit clinical heterogeneity, with some patients experiencing an indolent course. Survival can be predicted using clinical and biologic characteristics.
UR - http://www.scopus.com/inward/record.url?scp=70349231440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349231440&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-03-210591
DO - 10.1182/blood-2009-03-210591
M3 - Article
C2 - 19414856
AN - SCOPUS:70349231440
SN - 0006-4971
VL - 114
SP - 957
EP - 964
JO - Blood
JF - Blood
IS - 5
ER -